Fat Emulsion Dosage

Usual Adult Dose for Dietary Supplement

Usual dosage: 1 to 2 g/kg/day, IV

• Initial infusion rate should be 0.1 g/min for the first 15 to 30 minutes.
• May gradually increase rate after 30 minutes if tolerated.
• Maximum rate should not exceed 0.1 g/kg/hour.
• Duration of infusion is from 12 to 24 hours, depending on clinical situation.
• Maximum dose: 2.5 grams/kg/day, also, the daily dose should not exceed a maximum of 60% of total energy requirements.

Comments:

• Recommended dosage depends on age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize, and consideration of additional energy given to the patient.
• Take energy supplied by dextrose and amino acids, as well as enteral nutrition into account when determining dose.
• Correct severe fluid and electrolyte disorders prior to administration.
• The daily dose should not exceed 60% of total energy requirements.
• Obtain a baseline serum triglyceride level; if triglycerides are elevated, initiate at a lower dosage and advance in smaller increments, monitoring triglyceride levels with each adjustment.

Use: Parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated

Usual Pediatric Dose for Dietary Supplement

Birth to 2 years old (including preterm and term infants):
Initial dose: 0.5 to 1 g/kg/day

• Increase the dose by 0.5 to 1 g/kg/day

Maximum dose: 3 g/kg/day

• Duration of infusion: 20 to 24 hours for preterm and term neonates, and 12 to 24 hours for patients 1 month to 2 years

2 years to less than 12 years old:
Initial dose: 1 to 2 g/kg/day

• Increase the dose by 0.5 to 1 g/kg/day

Maximum dose: 3 g/kg/day

• Duration of infusion: 12 to 24 hours

12 to 17 years old:
Initial dose: 1 to 2 g/kg/day
Maximum dose: 2.5 g/kg/day

• Duration of infusion: 12 to 24 hours

Comments:

• Recommended dosage depends on age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize, and consideration of additional energy given to the patient.
• The duration of infusion will vary depending on the clinical situation but infuse over a longer duration in neonates.
• Do not exceed an infusion rate of 0.15 g/kg/h.
• The administration flow rate is determined by dividing the volume of lipid by the duration of the infusion.

Use: Parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated

Renal Dose Adjustments

Data not available

• Aluminum toxicity may develop in patients with impaired kidney function.

Liver Dose Adjustments

Use with caution.

• Monitor liver function closely, as hepatobiliary disorders are known to develop in some patients.

Precautions

CONTRAINDICATIONS:

• Known hypersensitivity to fish, egg, soybean, peanut protein, or to any of the active or inactive ingredients- Severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1,000 mg/dL)

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• This product is for intravenous infusion only into a peripheral or central vein.
• When given with dextrose and amino acids, the choice of central or peripheral administration should depend on the osmolarity of the final infusion:
• If osmolarity is 900 mOsm/L or higher it must be infused through a central vein.
• Less than 900 mOsm/L may be administered either through central or peripheral vein.
• Use a dedicated line for parenteral nutrition.
• Use a 1.2 micron in-line filter.

Storage requirements:

• Once removed from the overpouch, store at 2C to 8C (36F to 46F) for no longer than 24 hours.

Reconstitution/preparation techniques:

• Read the US FDA-approved patient labeling for further preparation and administration instructions.

Monitoring:

• The lipids in this product may interfere with some blood tests (e.g. hemoglobin, lactate dehydrogenase, bilirubin, and oxygen saturation) if blood is sampled before lipids have cleared from the bloodstream.
• Lipids are normally cleared 5 to 6 hours after the lipid infusion is stopped.
• Monitor fluid status closely in patients with pulmonary edema or heart failure.
• Routinely monitor serum triglycerides, fluid and electrolyte status, blood glucose, liver and kidney function, blood count including platelets, and coagulation parameters throughout treatment.
• Monitoring for signs and symptoms of essential fatty acid deficiency (EFAD) is recommended.
• Consult reference values of serum fatty acid level tests to determine adequacy of essential fatty acid status.
• Increasing essential fatty acid intake (enterally or parenterally) is effective in treating EFAD.

Patient advice:

• Read the Patient Information and Instructions for Use.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer